New Perspectives about Drug Candidates Targeting HTLV-1 and Related Diseases
MCM Silva, RSB Pereira, ACA Araujo, EGS Filho… - Pharmaceuticals, 2023 - mdpi.com
Among the human T-lymphotropic virus (HTLV) types, HTLV-1 is the most prevalent, and it
has been linked to a spectrum of diseases, including HAM/TSP, ATLL, and hyperinfection …
has been linked to a spectrum of diseases, including HAM/TSP, ATLL, and hyperinfection …
Future perspectives on drug targeting in adult T cell leukemia-lymphoma
Human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell
leukemia/lymphoma (ATL), HTLV-1 associated myelopathy (HAM/TSP), and of a number of …
leukemia/lymphoma (ATL), HTLV-1 associated myelopathy (HAM/TSP), and of a number of …
Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review
S Nakahata, D Enriquez-Vera, MI Jahan, K Sugata… - Biomolecules, 2023 - mdpi.com
Human T-cell leukemia virus type-1 (HTLV-1) causes adult T-cell leukemia/lymphoma (ATL).
HTLV-1 carriers have a lifelong asymptomatic balance between infected cells and host …
HTLV-1 carriers have a lifelong asymptomatic balance between infected cells and host …
Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma
M Yoshimitsu, N Arima - Blood and Lymphatic Cancer: Targets and …, 2014 - Taylor & Francis
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by latent
infection of human T-cell lymphotropic virus type 1. The outcome for ATLL is very poor, with …
infection of human T-cell lymphotropic virus type 1. The outcome for ATLL is very poor, with …
HTLV-1-associated T-cell diseases
K Tsukasaki, K Tobinai - T-cell lymphomas, 2012 - Springer
Adult T-cell leukemia-lymphoma (ATL) is a distinct peripheral T-lymphocytic malignancy
etiologically associated with human T-cell lymphotropic virus type I. The diversity in clinical …
etiologically associated with human T-cell lymphotropic virus type I. The diversity in clinical …
[HTML][HTML] Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all?
W Johnson, A Mishra, A Binder, A Gru, P Porcu - Haematologica, 2019 - ncbi.nlm.nih.gov
The human T-cell lymphotropic (or leukemia) virus type-1 (HTLV-1) was isolated by Poiesz
et al. in 1980 from the T-cell line Hut-102, established from a patient thought to have …
et al. in 1980 from the T-cell line Hut-102, established from a patient thought to have …
Therapeutic approaches for HTLV-1-associated adult T-cell leukemia/lymphoma: a comprehensive review
A Letafati, R Soheili, M Norouzi, P Soleimani… - Medical Oncology, 2023 - Springer
Adult T-cell leukemia/lymphoma (ATLL), an infrequent malignancy resultant from human T-
cell lymphotropic virus type I (HTLV-1), exhibits a spectrum of phenotypes, encompassing …
cell lymphotropic virus type I (HTLV-1), exhibits a spectrum of phenotypes, encompassing …
Design, rational repurposing, synthesis, in vitro evaluation, homology modeling and in silico study of Sulfuretin Analogs as Potential Antileishmanial hit compounds
AHE Hassan, TN Phan, Y Choi, S Moon, JH No… - Pharmaceuticals, 2022 - mdpi.com
Direct growth inhibition of infectious organisms coupled with immunomodulation to
counteract the immunosuppressive environment might be a beneficial therapeutic approach …
counteract the immunosuppressive environment might be a beneficial therapeutic approach …
Molecular pathology of HTLV-1
U Bertazzoni, V Ciminale, MG Romanelli - Frontiers in Microbiology, 2018 - frontiersin.org
Human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus discovered. It is
estimated that 10–20 million people are infected worldwide by this oncogenic virus. About 5 …
estimated that 10–20 million people are infected worldwide by this oncogenic virus. About 5 …
Chalcones identify cTXNPx as a potential antileishmanial drug target
DO Escrivani, RL Charlton, MB Caruso… - PLoS neglected …, 2021 - journals.plos.org
With current drug treatments failing due to toxicity, low efficacy and resistance; leishmaniasis
is a major global health challenge that desperately needs new validated drug targets …
is a major global health challenge that desperately needs new validated drug targets …